Difference between revisions of "Genentech, Inc. patent applications published on March 21st, 2024"
Wikipatents (talk | contribs) (Creating a new page) |
Wikipatents (talk | contribs) |
||
Line 1: | Line 1: | ||
+ | '''Summary of the patent applications from Genentech, Inc. on March 21st, 2024''' | ||
+ | |||
+ | Genentech, Inc. has recently filed patents for innovative technologies in the fields of antiviral therapies, cell culture media optimization, bispecific antigen-binding molecules for cancer treatment, and interleukin-33 antibodies for IL-33 mediated disorders. These patents cover methods of treating or preventing human cytomegalovirus infection, providing cell culture media for efficient cell growth and polypeptide production, developing bispecific antigen-binding molecules for targeted cancer therapy, and creating IL-33 antibodies for treating IL-33 mediated disorders like ocular diseases. | ||
+ | |||
+ | Summary of notable applications: | ||
+ | * Development of new antiviral therapies targeting human cytomegalovirus infection. | ||
+ | * Optimization of cell culture media for enhanced cell growth and polypeptide production. | ||
+ | * Utilization of bispecific antigen-binding molecules for more precise and effective cancer treatment. | ||
+ | * Creation of IL-33 antibodies for treating IL-33 mediated disorders, particularly ocular diseases like AMD. | ||
+ | |||
+ | |||
+ | |||
+ | |||
==Patent applications for Genentech, Inc. on March 21st, 2024== | ==Patent applications for Genentech, Inc. on March 21st, 2024== | ||
Latest revision as of 08:31, 27 March 2024
Summary of the patent applications from Genentech, Inc. on March 21st, 2024
Genentech, Inc. has recently filed patents for innovative technologies in the fields of antiviral therapies, cell culture media optimization, bispecific antigen-binding molecules for cancer treatment, and interleukin-33 antibodies for IL-33 mediated disorders. These patents cover methods of treating or preventing human cytomegalovirus infection, providing cell culture media for efficient cell growth and polypeptide production, developing bispecific antigen-binding molecules for targeted cancer therapy, and creating IL-33 antibodies for treating IL-33 mediated disorders like ocular diseases.
Summary of notable applications:
- Development of new antiviral therapies targeting human cytomegalovirus infection.
- Optimization of cell culture media for enhanced cell growth and polypeptide production.
- Utilization of bispecific antigen-binding molecules for more precise and effective cancer treatment.
- Creation of IL-33 antibodies for treating IL-33 mediated disorders, particularly ocular diseases like AMD.
Contents
- 1 Patent applications for Genentech, Inc. on March 21st, 2024
- 1.1 VIAL ASSEMBLY WITH LUER FITTING (18510516)
- 1.2 METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA (18501909)
- 1.3 ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF (18364185)
- 1.4 BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE (18517327)
- 1.5 CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION (18497162)
- 1.6 METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS (18518715)
Patent applications for Genentech, Inc. on March 21st, 2024
VIAL ASSEMBLY WITH LUER FITTING (18510516)
Main Inventor
Geoffrey WISE
METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA (18501909)
Main Inventor
Ahmed Hamed SALEM
ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF (18364185)
Main Inventor
Gerald R. NAKAMURA
BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE (18517327)
Main Inventor
Diego ELLERMAN
CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION (18497162)
Main Inventor
Natarajan Vijayasankaran
METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS (18518715)
Main Inventor
Claudio CIFERRI